Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2A | P28223 | 14/20 | 0.54 |
| ▸ | KCNH2 | Q12809 | 12/20 | 0.54 |
| ▸ | HTR2C | P28335 | 9/20 | 0.54 |
| ▸ | DRD2 | P14416 | 5/20 | 0.47 |
| ▸ | CNR1 | P21554 | 4/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11821618 | 0.81 | HTR2A (0.74) | HTR2AKCNH2HTR2CDRD2 | |
| SCHEMBL1173816 | 0.78 | PARP1 (0.52) | HTR2AKCNH2HTR2CDRD2 | |
| SCHEMBL1173665 | 0.73 | KIF11 (0.55) | HTR2AKCNH2HTR2CDRD2CNR1 | |
| SCHEMBL28465778 | 0.73 | HTR2A (0.81) | HTR2AKCNH2HTR2CDRD2 | |
| SCHEMBL3841026 | 0.73 | HTR2A (0.55) | HTR2AKCNH2HTR2CDRD2 | |
| SCHEMBL5423719 | 0.72 | HTR2A (0.47) | HTR2AKCNH2HTR2CDRD2 | |
| Hydrochloric Acid SCHEMBL5423933 | 0.71 | HTR2A (0.46) | HTR2AKCNH2HTR2CDRD2 | |
| SCHEMBL31060925 | 0.71 | HTR2A (1.00) | HTR2AKCNH2HTR2CDRD2 | |
| SCHEMBL7962369 | 0.71 | HTR2A (1.00) | HTR2AKCNH2HTR2CDRD2 | |
| SCHEMBL5198654 | 0.71 | PARP1 (0.52) | HTR2AKCNH2HTR2CDRD2CNR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070167447-A1 | Indole acetamides as inhibitors of the hepatitis c virus ns5b polymerase | ISTITUTO DI RICERCHE DI BIOLOGIA DI MOLECULOARE P. ANGELETTI SPA (IT) | 2007-07-19 | — | — | US | disclosed |
| EP-1613634-A1 | INDOLE ACETAMIDES AS INHIBITORS OF THE HEPATITIS C VIRUS NS5B POLYMERASE | ISTITUTO DI RICERCHE DI BIOLOGIA MOLECOLARE P. ANGELETTI S.P.A. (IT) | 2006-01-11 | — | — | EP | disclosed |
| WO-2004087714-A1 | INDOLE ACETAMIDES AS INHIBITORS OF THE HEPATITIS C VIRUS NS5B POLYMERASE | ISTITUTO DI RICERCHE DI BIOLOGIA MOLECOLARE P ANGELETTI SPA (IT) | 2004-10-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070167447-A1 | Indole acetamides as inhibitors of the hepatitis c virus ns5b polymerase | IDO1, NAT1, AANAT | HTR2A 248/4885KCNH2 2111/4885HTR2C 80/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.